Launching the Medical Support business using D2C expertise and data
First written in FY2022-Q3. 15 of 18 entries say "Advanced", first in FY2022. Latest entry: 2026-08-20.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「As a result, full-year segment revenue for the business was ¥999.012 million, up 59.3% year on year, and segment profit was ¥216.103 million, up 237.7%.」
Stronger sales coverage, more partner clinics and strong raw-material sales lifted Medical Support revenue to ¥999.012 million and segment profit to ¥216.103 million. - FY2025-H1AdvancedAnnual report
「In our core blood-derived processing services business, we strengthened the sales organization through optimal personnel allocation and additional hiring and worked to deepen relationships with partner clinics. As a result, outsourced processing orders in orthopedics and AGA treatment have grown steadily, including reaching a record high since services began in March.」
The company strengthened sales staffing and relationships with partner clinics. Orders in orthopedics and AGA reached a record high since service launch. Medical Support revenue was ¥331.854 million, up 49.5%, while segment loss narrowed to ¥8.594 million. - FY2024AdvancedAnnual report
「As a result, full-year segment revenue for the business was ¥627.074 million, up 276.6% year on year, and segment profit was ¥64.001 million, compared with a segment loss of ¥48.247 million.」
The Medical Support business progressed from a segment loss to profit as blood-derived processing services and Cellpro Japan’s raw-material sales drove substantial revenue growth. - FY2024-Q2AdvancedAnnual report
「We actively promoted sales proposals to clinics nationwide to introduce outsourced blood-derived processing services, and new partner clinics and outsourced processing orders increased steadily.」
Sales proposals continued nationwide, while new partner clinics and outsourced processing orders accumulated. Cellpro Japan’s raw-material sales also contributed after consolidation; segment revenue was ¥221.969 million and segment loss was ¥41.524 million. - FY2024-Q1AdvancedAnnual report
「In the Medical Support business, we actively promoted sales proposals to clinics nationwide to introduce outsourced blood-derived processing services. New partner clinics and outsourced processing orders increased steadily. Because improving the order-conversion rate among partner clinics is important for future growth, we increased visits to existing partner clinics, carefully gathered requests from clinic directors and patients, and actively pursued measures and investments to improve services. As a result, first-quarter consolidated cumulative-period revenue was ¥64.368 million, up 423.15% year on year, and segment loss was ¥61.545 million, compared with segment profit of ¥3.312 million a year earlier.」
The company expanded nationwide sales proposals, added partner clinics and outsourced processing orders, and increased visits to existing partners. Revenue rose 423.15% year on year, but segment loss was ¥61.545 million. - FY2023AdvancedAnnual report
「From the second quarter of the fiscal year, we fully rolled out proposals to introduce blood-derived processing services to orthopedic clinics and other facilities nationwide. As a result, the number of partner clinics and outsourced processing orders remained steady.」
Nationwide rollout accelerated from the second quarter. Full-year revenue was ¥166.504 million and segment loss was ¥48.247 million. - FY2023-Q3AdvancedAnnual report
「In the Medical Support business, we continued actively proposing the introduction of blood-derived processing therapy and worked to increase the number of partner clinics and outsourced processing orders.」
The company continued nationwide proposals for blood-derived processing therapy and sought more partner clinics and outsourced processing orders. Third-quarter cumulative-period revenue was ¥104.145 million and segment loss was ¥27.810 million. - FY2023-Q2AdvancedAnnual report
「In the Medical Support business, we actively proposed and supported the introduction of blood-derived processing (CPRP-FD) to orthopedic clinics nationwide and worked to expand partner medical institutions. As a result, second-quarter consolidated cumulative-period revenue was ¥40.978 million and segment loss was ¥2.140 million.」
The company expanded proposals for CPRP-FD nationwide. Revenue was ¥40.978 million, while segment loss was ¥2.140 million. - FY2023-Q1AdvancedAnnual report
「In the Medical Support business, in addition to promoting business-support services such as advertising production for medical clinics, we developed outsourced sales services for blood-derived processing and adipose-derived stem-cell processing by combining the strengths of SBC Medical Group and the company, and worked to expand partner medical institutions. As a result, first-quarter consolidated cumulative-period revenue was ¥12.304 million and segment profit was ¥3.312 million.」
The company expanded from advertising production for clinics into outsourced sales services for blood-derived and adipose-derived stem-cell processing and increased partner medical institutions. - FY2022AdvancedAnnual report
「For the consolidated fiscal year, revenue was ¥200.008 million and segment profit was ¥156.266 million.」
The Medical Support business, launched in the third quarter, generated full-year revenue of ¥200.008 million and segment profit of ¥156.266 million. - FY2022-Q3First statedAnnual report
「In the Medical Support business, we launched business-support services based on expertise developed in the D2C business, including advertising analysis, proposal planning and LP production, together with accumulated data. As a result, revenue for the third-quarter cumulative period was ¥50.000 million and segment profit was ¥44.494 million.」
The company launched business-support services based on D2C expertise and data. Third-quarter cumulative-period revenue was ¥50.000 million and segment profit was ¥44.494 million.